12:00 AM
 | 
Jan 16, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Relovair fluticasone furoate/vilanterol: Pivotal trial data

Top-line data from a 4-week, Phase III lung function profile trial in 54 patients showed that 50/25 µg, 100/25 µg, and 200/25 µg Relovair fluticasone furoate/vilanterol significantly increased weighted mean FEV1 vs. placebo. Last year, the companies reported data from...

Read the full 177 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >